| Field | Specification |
|---|---|
| Alternative names | GS-5885 D-tartrate |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C53H60F2N8O12 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Ledipasvir D-tartrate, also known as GS-5885 D-tartrate, is an inhibitor of hepatitis C virus NS5A, with EC50 values of 34 pM against the GT1a replicon and 4 pM against the GT1b replicon. It is supplied as an off-white to yellow solid (C53H60F2N8O12, MW 1039.09) at 99.20% purity.
Physical & Chemical Properties
| CAS Number | 1502654-87-6 |
|---|---|
| Molecular Formula | C53H60F2N8O12 |
| Molecular Weight | 1039.09 g/mol |
| Purity | 99.20% |
| Appearance | Solid |
| Color | Off-white to yellow |
| SMILES | O=C(OC)N[C@H](C(N([C@H](C1=NC=C(C2=CC(C(F)(F)C3=C4C=CC(C5=CC=C6N=C([C@H]7N(C([C@@H](NC(OC)=O)C(C)C)=O)[C@]8([H])CC[C@@]7([H])C8)NC6=C5)=C3)=C4C=C2)N1)C9)CC%109CC%10)=O)C(C)C.O[C@@H]([C@@H](C(O)=O)O)C(O)=O |
| Signaling Pathway | Anti-infection |
| Solubility | In Vitro: DMSO: 25 mg/mL (24.06 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
Activity & Target
EC50: 34 pM (GT1a), 4 pM (GT1b)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 25 mg/mL (24.06 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (2.41 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (2.41 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
EC50 values of Ledipasvir are 31 pM and 4 pM for GT1a and 1b, respectively, with protein-adjusted EC50 values of 210 pM (GT1a) and 27 pM (GT1b). The intrinsic EC50 is 310 fM against GT1a and 40 fM against GT1b. In human serum, as well as in the replicon assay cell-culture medium (containing 10% BSA), Ledipasvir is highly protein-bound[1]. Against the JFH/3a-NS5A replicon, Ledipasvir exhibits an EC50 value of 141 nM[2].
In Vivo
Ledipasvir stands out not just through its high replicon potency, but also through good bioavailability, low clearance, and long half-lives in rat, dog, and monkey, together with low predicted clearance in human. Rats and dogs are used to measure the pharmacokinetics of Ledipasvir. In plasma, half-lives of Ledipasvir are good (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr), systemic clearance (CL) is low, and volumes of distribution (Vss) are moderate and exceed total body water volume[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther 2021 May 29;6(1):212. PMID: 34052830
Hepatitis C virus diversity and treatment outcomes in Benin: a prospective cohort study. Lancet Microbe 2024 Jul;5(7):697-706. PMID: 38889738
Single-cell profiling of SLC family transporters: uncovering the role of SLC7A1 in osteosarcoma. J Transl Med 2025 Jan 22;23(1):103. PMID: 39844299
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci U S A 2017 Feb 21;114(8):1922-1927.
Targeting Phosphatidylinositol 4-Kinase IIIα for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent. Int J Radiat Oncol Biol Phys 2016 Nov 15;96(4):867-876.
Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure. Ann Hepatol 2019 Nov-Dec;18(6):816-824. PMID: 31594756
Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. Pharmaceuticals (Basel) 2022 Feb 18;15(2):242. PMID: 35215354
Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. J Gastroenterol 2019 May;54(5):449-458.
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. Antiviral Res 2017 Mar:139:18-24.
Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach. Antimicrob Agents Chemother 2015;59(6):3482-92. PMID: 25845863
